Comparative effects of A1 versus A2 milk on gastrointestinal symptoms and systemic exposure to beta-casomorphin-7 (BCM7)
Not Applicable
Completed
- Conditions
- Gastrointestinal symptoms related to milk intoleranceOral and Gastrointestinal - Normal oral and gastrointestinal development and functionDiet and Nutrition - Other diet and nutrition disorders
- Registration Number
- ACTRN12611000740998
- Lead Sponsor
- Curtin University of Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Caucasian
Do not drink more than 1 serve milk/day
Those who report lactose intolerance but have not received medial diagnosis
Willing to consume milk for 8 weeks
Able to sign and understand informed consent
Exclusion Criteria
Milk allergy
Diagnosed lactose intolerance
Pregnancy and lactation
Cardiovascular event in the last 6 months
Current, habitual opioid consumption
Antibiotic treatment within the last 8 weeks prior to screening
Immunosuppressive medications or anti-inflammatory drugs within the last 4 weeks prior to screening
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastrointestinal symptom management.<br>Participants will record gastrointestinal symptoms of intolerance in their Symptom Report Diary and daily bowel movement frequency/stool consistency using the Bristol Stool Scale.[Symptoms recorded during each 2 week intervention period]
- Secondary Outcome Measures
Name Time Method Investigation of the presence of BCM-7 in serum from fasting and postprandial blood samples[At the beginning and end of each 2 week intervention period<br>1 hour postprandial sample after consumption of 500mL of milk intervention at the end of each 2 week intervention period];Measurement of gastrointestinal tract permeability from a dual sugar test and urine analysis[At the end of each 2 week intervention period];Measurement of gut inflammation from analysis of faecal calprotectin to investigate possible precursors to BCM-7 effects[At the end of each 2 week intervention period]